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Reply
We appreciate the opportunity to reply to questions raised by Dr.
Nakazawa and colleagues. Please note that the coronary arteries
distal to the stented segment but not the stented lesion were
examined for the endothelial vasomotor function in our study (1).
As described in our study (1), myocardial ischemia-reperfusion
induces endothelial injury in the coronary trees for their entirety
distal to the occluded segment in the infarct-related coronary
artery. Thus, the healing process of the coronary arteries distal to
the stented segment but not the stented lesion affected our data.
Our previous reports (2–5) agreed that the atherosclerotic burden
strongly affects coronary endothelial vasomotor functions. How-
ever, our study (1) showed that the frequencies of the atheroscle-
rotic risk factors were comparable between the drug-eluting stent
(DES) and bare-metal stent (BMS) groups. In addition, the 2
groups had no difference in cardiac medications, lesion, and
procedural variables of percutaneous coronary intervention except
for stent selection, and acute myocardial infarction (AMI)–related
variables that potentially influence the coronary endothelial vaso-
motor function, as described in our study (1). Thus, the implanted
stents were only the discriminate factor for the difference in the
coronary endothelial vasomotor responses to acetylcholine between
the patients treated with BMS and DES.
A number of previous reports (6,7) demonstrated that the
vascular endothelial growth factor (VEGF) expression is increased
in cardiomyocytes as well as vascular endothelial cells in ischemic
or injured hearts and that sirolimus is capable of inhibiting VEGF
production and the VEGF-mediated cellular signaling pathway in
various types of cells. Our study (1) also showed that VEGF levels
in the anterior interventricular vein (AIV), reflecting VEGF levels
released from the ischemic myocardium, were increased in AMI
patients treated with BMS compared with control subjects. As we
described in our study (1), sirolimus levels in AIV in our study
were 10- to 500-fold lower than the levels to exert its biological
effects in vitro experiments (8,9). Considering the fact that
sirolimus is eluted into coronary circulation over a period of 4
weeks, these exposure times were much longer as compared with
the in vitro experiments. Moreover, the chronic exposure to the
circulating sirolimus might cause a local accumulation of consid-
erable amounts of this drug in the myocardium and the entire
vascular bed distal to sirolimus-eluting stent (SES) in the infarct-
related coronary artery. Thus, there is a possibility that SES could
induce a decrease in VEGF release from myocardium and endo-
thelium of large and resistance vessels, which may play a possible
role in the mechanisms for endothelial vasomotor dysfunction in
the infarct-related coronary arteries treated with SES.
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Early Detection of
Rheumatic Heart Disease
and Prevention of Heart
Failure in Sub-Saharan Africa
In a recent issue of the Journal, Damasceno et al. (1) highlighted
the need for action to reduce the prevalence of heart failure in
sub-Saharan Africa, where this pathology is an important cause of
mortality as well as a serious economic burden. Rheumatic heart
disease is the most frequent cause of heart failure in this region of
the world and is responsible for at least one-third of cases. In this
context, the authors are prudent to insist on the need for a strategy
of prevention with regards to risk factors for heart failure. Never-
theless, we would like to underline important new findings that
should be considered when attempting to reduce the incidence of
this life-threatening pathology.
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Recently, an echocardiographic approach demonstrated that the
prevalence of rheumatic heart disease in sub-Saharan Africa was
10 higher than previously reported (2). In other words, 9 out of
10 children have only minor infra-clinical rheumatic valve lesions
and would not have been detected by the clinical criteria used in
previous surveys. Secondary prophylaxis measures, based on monthly
penicillin injections in children after a first episode of acute rheumatic
fever and continued until the third decade, have been shown to be
inexpensive and efficient. This therapeutic strategy is best delivered as
part of a register-based control program, providing education and
enabling better clinical follow-up. This approach has been recom-
mended by the World Health Organization and the World Heart
Federation since the 1980s.
Comprehensive echocardiographic screening programs could
also enhance effective prevention strategies for rheumatic heart
disease. Early detection of “subclinical” rheumatic valve disease is
vital, as it presents an opportunity for case detection at a time when
prophylactic penicillin can prevent progression to clinical valve
disease and heart failure in young adult life.
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Reply
We agree with Drs. Marijon and Jouven that the time has come for
the adoption of echocardiographic screening as part of a strategy
for the early detection of rheumatic heart disease in endemic
regions of the world such as Africa, Southeast Asia, and the
Asia-Pacific region. The Pan African Society of Cardiology
(PASCAR) has called for the implementation of the Awareness-
Surveillance-Advocacy-Prevention (A.S.A.P.) Programme for the
prevention of rheumatic fever and rheumatic heart disease in
Africa, which embraces echocardiographic screening as part of an
effort to rid the continent of the scourge of rheumatic heart disease
“in our own lifetime” (1,2).
Although we agree with the overall thrust of the comment by
Drs. Marijon and Jouven, the statement that “rheumatic heart
disease is the most frequent cause of heart failure in this region of
the world” may only apply to children and young adults. A pooling
study of 12 hospital-based case series involving 4,548 patients from
8 countries (Cameroon, Ghana, Kenya, Nigeria, Senegal, South
Africa, Uganda, and Zimbabwe) has shown that hypertension
(23%) is the leading cause of heart failure in sub-Saharan Africa,
followed closely by rheumatic heart disease (22%), and cardiomy-
opathy (20%) (3).
Finally, the natural history of patients with “subclinical” (i.e., no
history of rheumatic fever, no symptoms, no signs, no mitral
stenosis) echocardiographic features suggestive of rheumatic heart
disease that were detected in the study by Marijon et al. (4) is
unknown. Studies are needed to examine the appropriate manage-
ment of these cases with borderline abnormalities that are likely to
be found in large numbers in through echocardiographic screening
for rheumatic heart disease.
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